The objectives of this trial will be to assess safety, tolerability and pharmacokinetics of single and multiple ascending doses of VTX-1463 in approximately 30 healthy volunteers. The trial is being conducted in the Netherlands.
Robert Hershberg, chief medical officer of VentiRx, said: “We are pleased to advance VTX-1463 into the clinic. This is another milestone for our toll-like receptor 8 effort as this is the second clinical program initiated in the last six months.”